A new era in moderate- to- severe Atopic Dermatitis : Using Abrocitinb to get patients on the Right track
In this webinar, a detailed discussion is done on a new era in moderate- to- severe Atopic Dermatitis : Using Abrocitinb to get patients on the Right
Speakers : Dr. Sandipan Dhar ,Dr. Shireen Furtado ,Dr. Ramesh Bhat ,Dr. Debjit Kar ,Dr. Maitreyee Panda
Current Treatment approach to a mild to moderate atopic dermatitis patient
In this webinar, a detailed discussion is done on current treatment approach to a mild to moderate atopic dermatitis patient
Speakers : Dr Aseem Sharma - Moderator MD, DNB, MBA, FAGE, IFAAD, Chief Dermatologist, ,Dr Rajan T D - Speaker ,Dr Brijesh Nair - Speaker
Newer Advances in the Management of Atopic Dermatitis and Role of PDE4 Inhibitor
In this webinar, a detailed discussion is done on newer advances in the management of atopic dermatitis and role of PDE4 inhibitor.
Speakers : Dr. V K Somani - Moderator ,Dr. Manoj Parekh ,Dr. Carol Fernandes FERNANDES (MASCARENHAS) ,Dr. A K Lahiry ,Dr. D Indira
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge